Chung Sung-Jun, Getty Images
The Samsung logo at company headquarters in South Korea

Samsung Eyes First Entry into US Stock Markets

Aug. 21, 2015
A Samsung biotechnology affiliate will likely be listed next year on the Nasdaq, the first time Samsung will enter any American stock market.

SEOULSouth Korea’s dominant Samsung conglomerate will make its first entry into U.S. stock markets next year with the listing of a biotechnology affiliate, a company official said Friday.

The listing of Samsung Bioepis on the Nasdaq Stock Market is aimed at securing funds for investment in the field of biosimilars a new breed of drugs that mimic the effects of far more costly biologic drugs made from living cells.

“With an underwriter already designated, preparations are under way for the public stock listing of Bioepis in the first half of next year,” the Samsung official told AFP.

Bioepis will be the first Samsung affiliate to list in the United States.

Samsung Electronics, the world’s largest mobile phone maker which accounts for the lion’s share of the group’s sales and profits controls 46% of Samsung BioLogics, which in turn holds 90% of Bioepis.

The Samsung group is already remarkably diverse, with interests ranging from electronics to construction and shipbuilding, and sees biotechnology as a revenue growth engine for the future.

Copyright Agence France-Presse, 2015

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2017. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!